In the eye of the COVID-19 cytokine storm.
作者信息
Vaninov Natalie
机构信息
Sinai Immunology Review Project, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Nat Rev Immunol. 2020 May;20(5):277. doi: 10.1038/s41577-020-0305-6.
Abstract
摘要
相似文献
1
In the eye of the COVID-19 cytokine storm.在新冠病毒细胞因子风暴的视角下。
Nat Rev Immunol. 2020 May;20(5):277. doi: 10.1038/s41577-020-0305-6.
2
Coagulopathy as a Prodrome of Cytokine Storm in COVID-19-Infected Patients.凝血功能障碍作为新冠病毒感染患者细胞因子风暴的前驱症状
Front Med (Lausanne). 2020 Oct 23;7:572989. doi: 10.3389/fmed.2020.572989. eCollection 2020.
3
The Management of Cytokine Storm in COVID-19.新型冠状病毒肺炎细胞因子风暴的管理
Acta Med Indones. 2020 Jul;52(3):306-313.
4
Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.噬血细胞性淋巴组织细胞增生症：COVID-19 大流行引发的综述。
Rheumatol Int. 2021 Jan;41(1):7-18. doi: 10.1007/s00296-020-04636-y. Epub 2020 Jun 25.
5
Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients.托珠单抗治疗重型和危重型新型冠状病毒肺炎患者的临床疗效
World J Clin Cases. 2020 Sep 6;8(17):3763-3773. doi: 10.12998/wjcc.v8.i17.3763.
6
COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.COVID-19、肥大细胞、细胞因子风暴、心理压力和神经炎症。
Neuroscientist. 2020 Oct-Dec;26(5-6):402-414. doi: 10.1177/1073858420941476. Epub 2020 Jul 18.
7
Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification.COVID-19 患者经体外血液净化治疗后，细胞因子风暴得到成功控制，病情得到恢复。
Int J Infect Dis. 2020 Jul;96:618-620. doi: 10.1016/j.ijid.2020.05.065. Epub 2020 May 26.
8
Development and implementation of a COVID-19 near real-time traffic light system in an acute hospital setting.在急性医院环境中开发和实施 COVID-19 近实时信号灯系统。
Emerg Med J. 2020 Oct;37(10):630-636. doi: 10.1136/emermed-2020-210199. Epub 2020 Sep 18.
9
Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets.脓毒症相关细胞因子风暴中的 Toll 样受体及其内源性负性调节因子作为未来的免疫调节靶点。
Int Immunopharmacol. 2020 Dec;89(Pt B):107087. doi: 10.1016/j.intimp.2020.107087. Epub 2020 Oct 12.
10
Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?靶向淋巴细胞Kv1.3通道以抑制重症COVID-19中的细胞因子风暴：这能否成为一种新的治疗策略？
Drug Discov Ther. 2020 Jul 15;14(3):143-144. doi: 10.5582/ddt.2020.03046. Epub 2020 Jun 25.
引用本文的文献
1
Regulation of m7G methylation in long COVID: Expression profiles and early predictive value of key genes.长新冠中m7G甲基化的调控：关键基因的表达谱及早期预测价值
Medicine (Baltimore). 2025 Aug 29;104(35):e44209. doi: 10.1097/MD.0000000000044209.
2
Viral infections and related fatal adverse events associated with complement inhibitors for PNH: a real-world pharmacovigilance analysis in FAERS.阵发性睡眠性血红蛋白尿症补体抑制剂相关的病毒感染及相关致命不良事件：基于FAERS的真实世界药物警戒分析
Front Pharmacol. 2025 Aug 11;16:1639685. doi: 10.3389/fphar.2025.1639685. eCollection 2025.
3
Nanoparticle approaches for manipulating cytokine delivery and neutralization.用于调控细胞因子递送与中和的纳米颗粒方法。
Front Immunol. 2025 Jun 10;16:1592795. doi: 10.3389/fimmu.2025.1592795. eCollection 2025.
4
COVID-19-Related Spontaneous Vertebral Artery Dissection: A Case Report.新冠病毒相关的自发性椎动脉夹层：一例报告
Cureus. 2025 May 17;17(5):e84265. doi: 10.7759/cureus.84265. eCollection 2025 May.
5
Histopathological examination of lung from infant with lethal COVID-19 with special attention on pneumocytes type II and the immune infiltrate: a case study.对患有致命性新冠病毒病的婴儿肺部进行组织病理学检查，特别关注II型肺细胞和免疫浸润：一项病例研究。
Ital J Pediatr. 2025 Jun 7;51(1):174. doi: 10.1186/s13052-025-01984-y.
6
COVID-19 coagulopathy and antiphospholipid syndrome.新型冠状病毒肺炎凝血病与抗磷脂综合征
Rev Colomb Reumatol. 2022 Jun;29:S25-S34. doi: 10.1016/j.rcreu.2021.02.013. Epub 2021 Aug 27.
7
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy.新冠病毒感染、噬血细胞性淋巴组织细胞增生症和嵌合抗原受体T细胞疗法中的细胞因子风暴
JAMA Netw Open. 2025 Apr 1;8(4):e253455. doi: 10.1001/jamanetworkopen.2025.3455.
8
HDL proteome and apolipoproteins concentrations in severe ICU COVID-19 patients.重症监护病房（ICU）中重症新型冠状病毒肺炎（COVID-19）患者的高密度脂蛋白（HDL）蛋白质组和载脂蛋白浓度
Lipids Health Dis. 2025 Jan 31;24(1):32. doi: 10.1186/s12944-024-02381-w.
9
Blood Inflammatory Markers and Cytokines in COVID-19 Patients With Bacterial Coinfections.新冠病毒合并细菌感染患者的血液炎症标志物和细胞因子
Immun Inflamm Dis. 2024 Dec;12(12):e70105. doi: 10.1002/iid3.70105.
10
An exploratory analysis of associations of genetic variation with the efficacy of tocilizumab in severe COVID-19 patients. A pharmacogenetic study based on next-generation sequencing.对重症 COVID-19 患者中基因变异与托珠单抗疗效相关性的探索性分析。一项基于下一代测序的药物遗传学研究。
Front Pharmacol. 2024 Sep 13;15:1426826. doi: 10.3389/fphar.2024.1426826. eCollection 2024.
Zotero 插件